A Recommendation Against Serologic Screening for Genital Herpes Infection-What Now?

Editorial

. 2016 Dec 20;316(23):2493-2494.

doi: 10.1001/jama.2016.17139.

Affiliations

Editorial

Edward W Hook 3rd. JAMA. 2016.

. 2016 Dec 20;316(23):2493-2494.

doi: 10.1001/jama.2016.17139.

¹ School of Medicine, Department of Microbiology, The University of Alabama at Birmingham.

No abstract available

Comment on

Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Fife K, Selke S, Huang ML, Stobernack HP, Zimmermann H, Corey L, Birkmann A, Ruebsamen-Schaeff H. Wald A, et al. JAMA. 2016 Dec 20;316(23):2495-2503. doi: 10.1001/jama.2016.18189. JAMA. 2016. PMID: 27997653 Clinical Trial.
Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Recommendation Statement.
US Preventive Services Task Force; Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FA, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phillips WR, Phipps MG, Pignone MP, Silverstein M, Tseng CW. US Preventive Services Task Force, et al. JAMA. 2016 Dec 20;316(23):2525-2530. doi: 10.1001/jama.2016.16776. JAMA. 2016. PMID: 27997659
Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Feltner C, Grodensky C, Ebel C, Middleton JC, Harris RP, Ashok M, Jonas DE. Feltner C, et al. JAMA. 2016 Dec 20;316(23):2531-2543. doi: 10.1001/jama.2016.17138. JAMA. 2016. PMID: 27997660 Review.